Bezlotoxumab is a human monoclonal antibody directed against C. difficile toxin B. Bezlotoxumab binds to C. difficile toxin B preventing intestinal epithelial damage and colitis[1].
Human monoclonal antitoxin antibody:
Prevention of recurrence of Clostridium difficile
infection
Bezlotoxumab is catabolized through protein degradation
processes; metabolism does not contribute to its clearance.
It is eliminated from the body primarily by protein
degradation.
[1] Navalkele BD, et, al. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics. 2018 Jan 18;12:11-21. DOI:
10.2147/BTT.S127099
